Lucis banked €18.5M ($20M) in a Series A round led by General Catalyst. The Y Combinator alumnus had previously joined the accelerator in early 2024 following a pre-seed round in 2022.
The company operates an AI-powered preventative health platform designed to identify early-stage health risks. Subscribers pay a fee of approximately €200 to access a diagnostic suite that includes blood tests, epigenetic testing, and physiological monitoring. Lucis processes this biological data through its proprietary models, incorporating factors such as cardiovascular health, microbiome composition, and metabolic markers to provide personalised longevity roadmaps.
The startup currently manages a waitlist of 40,000 people and reports that 30% of its current users are based in France. With the new capital, Lucis plans to expand its physical footprint across Europe, with scheduled launches in Spain, Germany, and Italy by the end of 2024.
As health systems across Europe face increasing strain, investor interest is shifting toward consumer-led longevity tools that promise to reduce the long-term burden of chronic disease through proactive diagnostics.
Originally reported by Sifted.